<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2430">
  <stage>Registered</stage>
  <submitdate>14/07/2009</submitdate>
  <approvaldate>14/07/2009</approvaldate>
  <nctid>NCT00939874</nctid>
  <trial_identification>
    <studytitle>Switch From Tenofovir to Raltegravir for Low Bone Mineral Density</studytitle>
    <scientifictitle>Switch From Tenofovir to Raltegravir for Low Bone Mineral Density</scientifictitle>
    <utrn />
    <trialacronym>TROP</trialacronym>
    <secondaryid>TROP</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <healthcondition>Osteopenia</healthcondition>
    <healthcondition>Osteoporosis</healthcondition>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Raltegravir

Experimental: Raltegravir - 


Treatment: drugs: Raltegravir
Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips - Percent Change in Bone Mineral Density of Lumbar Spine and Hips from Baseline to Weeks 48 and 96</outcome>
      <timepoint>from Baseline to Weeks 48 and 96</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HIV Viral Load &lt;50 Copies/mL - Plasma HIV viral load remained &lt;50 copies/mL</outcome>
      <timepoint>from Baseline to Week 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. provision of written, informed consent

          2. HIV-infected adults at least 18 years of age

          3. receiving stable ART including TDF and a r/PI for the previous 6 months

          4. no prior PI genotypic resistance or known replication of HIV in patients receiving a
             PI

          5. plasma HIV RNA &lt; 50 copies/ml for at least the previous 3 months

          6. spine or neck of femur t-score = -1.0 (i.e. WHO-defined osteopenia) measured by dual
             energy x-ray absorptiometry (DEXA)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>7. participation in any other clinical trial (unless approved by the study PI)

          8. use of TDF for previously active chronic hepatitis B infection

          9. receiving or requiring therapy for low BMD (including prior fragility fracture)

         10. using oral corticosteroids or inhaled fluticasone

         11. virological failure on, or intolerance to, RAL

         12. contra-indication to RAL therapy (see appendix 2)

         13. breast-feeding

         14. pregnancy

         15. secondary, endocrinological cause of low BMD:25-hydroxy vitamin D deficiency,
             hypogonadism: a)symptomatic b)asymptomatic defined by total testosterone &gt; 25% below
             lower limit of reference range and/or luteinizing hormone &gt; 2 x upper limit of normal
             (ULN),untreated hypothyroidism or hyperparathyroidism according to local reference
             ranges</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>52</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>East Sydney Doctors - Sydney</hospital>
    <hospital>Holdsworth Medical Practice - Sydney</hospital>
    <hospital>St Vincents Hospital - Sydney</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital, Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Holdsworth House Medical Practice</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The Alfred</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if low bone mineral density (a measurement of how
      thick and strong bones are) improves in adults with HIV infection who switch their HIV
      medication tenofovir to another HIV medication raltegravir.

      Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic
      patients switching from ART including tenofovir disoproxil fumarate (TDF) and a
      ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00939874</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew D Carr, Professor</name>
      <address>St Vincents Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>